Reality of the ASPIRE Study

Ajai Chari, MD

Video Categories: ASH 2014

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate for a large portion of the myeloma population. The most practice changing piece of the study may be regarding the proven safety of carfilzomib.
July 17, 2018

Explaining Treatment Regimens to Patients with HR+/HER2–Metastatic Breast Cancer

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2–metastatic breast cancer regarding how long their treatment will last and how it will impact them.

November 19, 2014

Payer Coverage in Polycythemia Vera

Ken Schaecher, MD, Medical Director of SelectHealth, describes in his opinion how there is no payer coverage issues with patients with polycythemia vera at this time. Supported through funding from Incyte